Calcitriol will encounter a market that already has FDA-approved generic Calcitriol manufacturers. Companies already selling vitamin D will prove very competitive and may make it difficult for RMTI to capture significant market share. So betting on 50 million in Calcitriol sales anytime in the next several years is very wishful thinking.
Calcitriol should have already been marketed for at least 18 months. RMTI brought the ANDA in July 2011, It was approved at that time for marketing and for a specific manufacturing site. For some reason, marketing chose not to bring forth their Calcitriol at that time, but rather changed from the ANDA approved manufacturer which would require new stability testing and site inspection. So here we are pending approval for a product that was already approved 2 years ago for the original manufacturer.
you should go talk to the other idiot studying the daily charts. stupidity is bliss on this message board. the stock will remain in a relatively tight trading range until the SFP P3 news release. There's no reason for a steep spike or steep sell off until that news release. You are as dumb as a stump if this is novel to you.